SUTRO BIOPHARMA, INC.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-48.0M | $-58.2M | $31.1M | $-49.3M | $-38.5M | $-50.1M | $-34.6M | $-19.5M |
| Depreciation & Amortization | $1.8M | $1.8M | $1.7M | $1.7M | $1.7M | $1.6M | $1.5M | $1.4M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $6.2M | $6.1M | $6.2M | $6.0M | $6.7M | $6.0M | $5.9M | $6.8M |
| Net Cash from Operating Activities | $9.5M | $-64.7M | $14.1M | $-33.5M | $-31.2M | $-61.0M | $-23.9M | $65.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-80.4M | $64.1M | $-23.5M | $-114.0M | $66.2M | $67.5M | $-37.9M | $-78.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $96.5M | $-3.4M | $-3.1M | $-5.7M | $137.7M | $8.8M | $12.2M | $29.8M |
| Net Change in Cash | $25.6M | $-4.1M | $-12.6M | $-153.3M | $172.6M | $15.2M | $-49.5M | $17.7M |
| Free Cash Flow | — | — | — | — | — | — | — | — |